{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:48:20Z","timestamp":1793108900645,"version":"4.5.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jocn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.jocn.2023.08.016","type":"journal-article","created":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T22:48:28Z","timestamp":1692830908000},"page":"60-66","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Exploring the prescribing trends and factors affecting initial anti-parkinsonian drug selection in Korea: A nationwide population-based cohort study"],"prefix":"10.1016","volume":"116","author":[{"given":"Minhee","family":"Ku","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nam Kyung","family":"Je","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jocn.2023.08.016_b0005","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1474-4422(06)70471-9","article-title":"Epidemiology of Parkinson's disease","volume":"5","author":"de Lau","year":"2006","journal-title":"Lancet Neurol"},{"issue":"13","key":"10.1016\/j.jocn.2023.08.016_b0010","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/mds.25945","article-title":"The prevalence of Parkinson's disease: a systematic review and meta-analysis","volume":"29","author":"Pringsheim","year":"2014","journal-title":"Mov Disord"},{"issue":"S5","key":"10.1016\/j.jocn.2023.08.016_b0015","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s00415-008-5004-3","article-title":"Epidemiology of Parkinson\u2019s disease","volume":"255","author":"Alves","year":"2008","journal-title":"J Neurol"},{"issue":"5","key":"10.1016\/j.jocn.2023.08.016_b0020","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1474-4422(18)30499-X","article-title":"Global, regional, and national burden of neurological disorders, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"Feigin","year":"2019","journal-title":"Lancet Neurol"},{"issue":"S1","key":"10.1016\/j.jocn.2023.08.016_b0025","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/jnc.13691","article-title":"The clinical symptoms of Parkinson\u2019s disease","volume":"139","author":"Sveinbjornsdottir","year":"2016","journal-title":"J Neurochem"},{"issue":"4","key":"10.1016\/j.jocn.2023.08.016_b0030","first-page":"S87","article-title":"Parkinson\u2019s disease: health-related quality of life, economic cost, and implications of early treatment","volume":"16","author":"Chen","year":"2010","journal-title":"Am J Manag Care"},{"issue":"14","key":"10.1016\/j.jocn.2023.08.016_b0035","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1056\/NEJM199309303291408","article-title":"Treatment of Parkinson's disease","volume":"329","author":"Wood","year":"1993","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jocn.2023.08.016_b0040","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/mds.20464","article-title":"Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004","volume":"20","author":"Goetz","year":"2005","journal-title":"Movement Disord Off J Mov Disord Soc"},{"issue":"7","key":"10.1016\/j.jocn.2023.08.016_b0045","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1212\/01.wnl.0000215250.82576.87","article-title":"Practice Parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review):[RETIRED]: Report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"66","author":"Pahwa","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2023.08.016_b0050","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1212\/WNL.0b013e3181a1d44c","article-title":"The scientific and clinical basis for the treatment of Parkinson disease (2009)","volume":"72","author":"Olanow","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2023.08.016_b0055","series-title":"Levodopa (l-dopa). StatPearls [Internet]","author":"Gandhi","year":"2021"},{"issue":"23","key":"10.1016\/j.jocn.2023.08.016_b0060","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1056\/NEJMct0800326","article-title":"Levodopa for the Treatment of Parkinson's Disease","volume":"359","author":"LeWitt","year":"2008","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.jocn.2023.08.016_b0065","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1056\/NEJM200005183422004","article-title":"A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa","volume":"342","author":"Rascol","year":"2000","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jocn.2023.08.016_b0070","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/jnnp.68.6.685","article-title":"Dopamine agonists: their role in the treatment of Parkinson\u2019s disease","volume":"68","author":"Brooks","year":"2000","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2 Part 1","key":"10.1016\/j.jocn.2023.08.016_b0075","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1212\/WNL.41.2_Part_1.202","article-title":"Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson\u2019s disease","volume":"41","author":"Kostic","year":"1991","journal-title":"Neurology"},{"issue":"15","key":"10.1016\/j.jocn.2023.08.016_b0080","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1001\/jama.284.15.1931","article-title":"Pramipexole vs Levodopa as initial treatment for Parkinson DiseaseA randomized controlled trial","volume":"284","year":"2000","journal-title":"J Am Med Assoc"},{"issue":"5","key":"10.1016\/j.jocn.2023.08.016_b0085","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1212\/01.WNL.0000152880.77812.5B","article-title":"\u201cLevodopa phobia\u201d: a new iatrogenic cause of disability in Parkinson disease","volume":"64","author":"Kurlan","year":"2005","journal-title":"Neurology"},{"issue":"9949","key":"10.1016\/j.jocn.2023.08.016_b0090","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/S0140-6736(14)60683-8","article-title":"Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson\u2019s disease (PD MED): a large, open-label, pragmatic randomised trial","volume":"384","author":"Gray","year":"2014","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jocn.2023.08.016_b0095","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1001\/archneurol.2009.32","article-title":"Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease","volume":"66","year":"2009","journal-title":"Arch Neurol"},{"issue":"7","key":"10.1016\/j.jocn.2023.08.016_b0100","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1212\/01.wnl.0000310812.43352.66","article-title":"Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD","volume":"71","author":"Katzenschlager","year":"2008","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.jocn.2023.08.016_b0105","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/mds.23038","article-title":"Prescribing patterns of antiparkinsonian agents in Europe","volume":"25","author":"Rosa","year":"2010","journal-title":"Mov Disord"},{"issue":"5","key":"10.1016\/j.jocn.2023.08.016_b0110","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.parkreldis.2007.10.010","article-title":"Prescribing pattern of anti-Parkinson drugs in Southern Italy: cross-sectional analysis in the years 2003\u20132005","volume":"14","author":"Trifir\u00f2","year":"2008","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"10.1016\/j.jocn.2023.08.016_b0115","doi-asserted-by":"crossref","first-page":"241","DOI":"10.4046\/trd.2017.80.3.241","article-title":"Evaluation of appropriate management of chronic obstructive pulmonary disease in Korea: based on health insurance review and assessment service (HIRA) claims","volume":"80","author":"Chung","year":"2017","journal-title":"Tuberc Respir Dis"},{"issue":"4","key":"10.1016\/j.jocn.2023.08.016_b0120","doi-asserted-by":"crossref","first-page":"191","DOI":"10.17340\/jkna.2017.4.1","article-title":"The prevalence and incidence of Parkinson\u2032s disease in South Korea: A 10-year nationwide population-based study","volume":"35","author":"Lee","year":"2017","journal-title":"J Korean Neurol Assoc"},{"issue":"1","key":"10.1016\/j.jocn.2023.08.016_b0125","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1186\/s12877-019-1332-7","article-title":"Trends in the incidence and prevalence of Parkinson\u2019s disease in Korea: a nationwide, population-based study","volume":"19","author":"Park","year":"2019","journal-title":"BMC Geriatr"},{"issue":"1","key":"10.1016\/j.jocn.2023.08.016_b0130","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/mdc3.12568","article-title":"Epidemiology of Parkinson's disease\u2014east versus west","volume":"5","author":"Abbas","year":"2018","journal-title":"Mov Disord Clin Practice"},{"issue":"5","key":"10.1016\/j.jocn.2023.08.016_b0135","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/practneurol-2012-000210","article-title":"Prescribing in Parkinson's disease: a story of hope and adverse events","volume":"12","author":"Morrish","year":"2012","journal-title":"Pract Neurol"},{"issue":"8","key":"10.1016\/j.jocn.2023.08.016_b0140","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s00228-015-1881-4","article-title":"Trends in inpatient antiparkinson drug use in the USA, 2001\u20132012","volume":"71","author":"Crispo","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.jocn.2023.08.016_b0145","doi-asserted-by":"crossref","first-page":"e99021","DOI":"10.1371\/journal.pone.0099021","article-title":"Prescribing pattern of anti-Parkinson drugs in Japan: a trend analysis from 2005 to 2010","volume":"9","author":"Nakaoka","year":"2014","journal-title":"PLoS One"},{"issue":"S1","key":"10.1016\/j.jocn.2023.08.016_b0150","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1002\/ana.410440722","article-title":"Levodopa toxicity and apoptosis","volume":"44","author":"Melamed","year":"1998","journal-title":"Ann Neurol"},{"issue":"4 Supplement 1","key":"10.1016\/j.jocn.2023.08.016_b0155","first-page":"S9","article-title":"Neuroprotection and dopamine agonists","volume":"58","author":"Schapira","year":"2002","journal-title":"Neurology"},{"issue":"11 Suppl 5","key":"10.1016\/j.jocn.2023.08.016_b0160","first-page":"S1","article-title":"An algorithm (decision tree) for the management of Parkinson\u2019s disease (2001): treatment guidelines","volume":"56","author":"Olanow","year":"2001","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.jocn.2023.08.016_b0165","first-page":"469","article-title":"Guidelines for the management of Parkinson\u2019s disease. The Parkinson\u2019s Disease Consensus Working Group","volume":"59","author":"Bhatia","year":"1998","journal-title":"Hospital Med"},{"issue":"7","key":"10.1016\/j.jocn.2023.08.016_b0170","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1212\/01.wnl.0000206363.57955.1b","article-title":"Practice parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"66","author":"Suchowersky","year":"2006","journal-title":"Neurology"},{"issue":"9949","key":"10.1016\/j.jocn.2023.08.016_b0175","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/S0140-6736(14)60683-8","article-title":"Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial","volume":"384","author":"PD MED Collaborative Group","year":"2014","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jocn.2023.08.016_b0180","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1001\/archneurol.2010.65","article-title":"Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients","volume":"67","author":"Weintraub","year":"2010","journal-title":"Arch Neurol"},{"issue":"8","key":"10.1016\/j.jocn.2023.08.016_b0185","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/mds.27372","article-title":"International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson's disease","volume":"33","author":"Fox","year":"2018","journal-title":"Mov Disord"},{"key":"10.1016\/j.jocn.2023.08.016_b0190","doi-asserted-by":"crossref","first-page":"100257","DOI":"10.1016\/j.ensci.2020.100257","article-title":"Prescription pattern of anti-Parkinson\u2019s disease drugs in Japan based on a nationwide medical claims database","volume":"20","author":"Suzuki","year":"2020","journal-title":"eNeurologicalSci"},{"key":"10.1016\/j.jocn.2023.08.016_b0195","first-page":"1859321","article-title":"National Trends of Antiparkinsonism Treatment in Taiwan: 2004\u20132011","volume":"2016","author":"Liu","year":"2016","journal-title":"Parkinson\u2019s Disease"},{"issue":"5","key":"10.1016\/j.jocn.2023.08.016_b0200","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1368-5031.2005.00426.x","article-title":"Prescribing pattern in Parkinson\u2019s disease: are cost and efficacy overriding factors?","volume":"59","author":"Tan","year":"2005","journal-title":"Int J Clin Pract"},{"issue":"11","key":"10.1016\/j.jocn.2023.08.016_b0205","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2165\/00023210-200418110-00003","article-title":"The long-acting dopamine receptor agonist cabergoline in early Parkinson\u2019s disease","volume":"18","author":"Bracco","year":"2004","journal-title":"CNS Drugs"},{"issue":"8","key":"10.1016\/j.jocn.2023.08.016_b0210","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1007\/s00415-019-09360-7","article-title":"Real-world pharmacological treatment patterns of patients with young-onset Parkinson\u2019s disease in Japan: a medical claims database analysis","volume":"266","author":"Kasamo","year":"2019","journal-title":"J Neurol"},{"issue":"3","key":"10.1016\/j.jocn.2023.08.016_b0220","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/mdc3.12422","article-title":"Prevalence and correlates of anti-Parkinson drug use in a nationally representative sample","volume":"4","author":"Dahodwala","year":"2017","journal-title":"Mov Disord Clin Practice"},{"issue":"1","key":"10.1016\/j.jocn.2023.08.016_b0225","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1034\/j.1600-0404.2000.102001037.x","article-title":"Gender differences in Parkinson\u2019s disease symptom profile","volume":"102","author":"Scott","year":"2000","journal-title":"Acta Neurol Scand"},{"issue":"8","key":"10.1016\/j.jocn.2023.08.016_b0230","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/mds.21520","article-title":"Gender differences in patients with Parkinson's disease treated with subthalamic deep brain stimulation","volume":"22","author":"Accolla","year":"2007","journal-title":"Mov Disord"},{"issue":"7","key":"10.1016\/j.jocn.2023.08.016_b0235","doi-asserted-by":"crossref","first-page":"A876","DOI":"10.1016\/j.jval.2016.08.340","article-title":"The current treatment of Parkinson\u2019s Disease in Japan","volume":"19","author":"Uda","year":"2016","journal-title":"Value in Health"},{"issue":"9","key":"10.1016\/j.jocn.2023.08.016_b0240","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1212\/WNL.0b013e31822c6224","article-title":"Network correlates of the cognitive response to levodopa in Parkinson disease","volume":"77","author":"Mattis","year":"2011","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.jocn.2023.08.016_b0245","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1017\/S135561770808082X","article-title":"Levodopa improves time-based prospective memory in Parkinson's disease","volume":"14","author":"Costa","year":"2008","journal-title":"J Int Neuropsychol Soc"},{"issue":"2A","key":"10.1016\/j.jocn.2023.08.016_b0250","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1590\/S0004-282X2008000200001","article-title":"Working memory in Parkinson\u2019s disease patients: clinical features and response to levodopa","volume":"66","author":"Beato","year":"2008","journal-title":"Arq Neuropsiquiatr"},{"issue":"4","key":"10.1016\/j.jocn.2023.08.016_b0255","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00702-002-0811-7","article-title":"Pramipexole in comparison to l-dopa: a neuropsychological study","volume":"110","author":"Brusa","year":"2003","journal-title":"J Neural Transm"},{"issue":"1-2","key":"10.1016\/j.jocn.2023.08.016_b0260","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jns.2012.07.015","article-title":"The role of the dopaminergic system in mood, motivation and cognition in Parkinson's disease: a double blind randomized placebo-controlled experimental challenge with pramipexole and methylphenidate","volume":"320","author":"Drijgers","year":"2012","journal-title":"J Neurol Sci"},{"issue":"4","key":"10.1016\/j.jocn.2023.08.016_b0265","first-page":"341","article-title":"Comparative cognitive effects of levo-dopa plus carbidopa and dopamine agonist as an initial therapy of Parkinson\u2019s disease","volume":"26","author":"Park","year":"2008","journal-title":"J Korean Neurol Assoc"},{"issue":"12","key":"10.1016\/j.jocn.2023.08.016_b0270","first-page":"2046","article-title":"Parkinson\u2019s disease: diagnosis and treatment","volume":"74","author":"Rao","year":"2006","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.jocn.2023.08.016_b0275","doi-asserted-by":"crossref","first-page":"855323","DOI":"10.3389\/fpubh.2022.855323","article-title":"The different classification of hospitals impact on medical outcomes of patients in China","volume":"10","author":"Li","year":"2022","journal-title":"Front Public Health"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586823002163?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586823002163?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T21:33:52Z","timestamp":1760823232000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586823002163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":54,"alternative-id":["S0967586823002163"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2023.08.016","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring the prescribing trends and factors affecting initial anti-parkinsonian drug selection in Korea: A nationwide population-based cohort study","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2023.08.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}